These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 10618600)

  • 61. [Bisphosphonates in the treatment and prevention of bone metastases].
    Hoekman K; van Holten-Verzantvoort AT; Pinedo HM
    Ned Tijdschr Geneeskd; 1997 Nov; 141(46):2217-22. PubMed ID: 9550782
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Bisphosphonate therapy for patients with breast carcinoma.
    Plunkett TA; Rubens RD
    Cancer; 2003 Feb; 97(3 Suppl):854-8. PubMed ID: 12548586
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The use of bisphosphonates in patients with breast cancer.
    Van Poznak CH
    Cancer Control; 2002; 9(6):480-9. PubMed ID: 12514566
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.
    Hald A; Hansen RR; Thomsen MW; Ding M; Croucher PI; Gallagher O; Ebetino FH; Kassem M; Heegaard AM
    Int J Cancer; 2009 Sep; 125(5):1177-85. PubMed ID: 19444917
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease.
    Terpos E; Dimopoulos MA; Berenson J
    Crit Rev Oncol Hematol; 2011 Feb; 77 Suppl 1():S13-23. PubMed ID: 21353176
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients.
    Ali SM; Esteva FJ; Hortobagyi G; Harvey H; Seaman J; Knight R; Costa L; Lipton A
    J Clin Oncol; 2001 Jul; 19(14):3434-7. PubMed ID: 11454892
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Bisphosphonates: preclinical aspects and use in osteoporosis.
    Fleisch HA
    Ann Med; 1997 Feb; 29(1):55-62. PubMed ID: 9073324
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The role of bisphosphonates in breast cancer.
    Coleman RE
    Breast; 2004 Dec; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR; Saunders Y; Edmonds PM; Patel S; Wonderling D; Normand C; Broadley K
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [TBL] [Abstract][Full Text] [Related]  

  • 71. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
    Mühlbauer RC; Bauss F; Schenk R; Janner M; Bosies E; Strein K; Fleisch H
    J Bone Miner Res; 1991 Sep; 6(9):1003-11. PubMed ID: 1838661
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis.
    Palmieri C; Fullarton JR; Brown J
    Clin Cancer Res; 2013 Dec; 19(24):6863-72. PubMed ID: 24166910
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
    Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
    J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Should bisphosphonates be standard therapy for bone pain?
    Paterson AH
    Support Care Cancer; 1997 May; 5(3):200-4. PubMed ID: 9176965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.
    Paterson AH; Powles TJ; Kanis JA; McCloskey E; Hanson J; Ashley S
    J Clin Oncol; 1993 Jan; 11(1):59-65. PubMed ID: 8418243
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Bisphosphonate therapy in the oncology setting.
    Lipton A
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):469-88. PubMed ID: 14662000
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clodronate: a review of its use in breast cancer.
    Hurst M; Noble S
    Drugs Aging; 1999 Aug; 15(2):143-67. PubMed ID: 10495073
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials.
    Lipton A; Theriault RL; Hortobagyi GN; Simeone J; Knight RD; Mellars K; Reitsma DJ; Heffernan M; Seaman JJ
    Cancer; 2000 Mar; 88(5):1082-90. PubMed ID: 10699899
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Zoledronic acid for the treatment of bone metastases in patients with breast cancer and other solid tumors.
    Lacerna L; Hohneker J
    Semin Oncol; 2003 Oct; 30(5 Suppl 16):150-60. PubMed ID: 14613036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.